Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Pfizer (NYSE:PFE) and maintained a $45 price target on the stock.
January 31, 2024 | 6:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen reaffirmed an Overweight rating on Pfizer and maintained a $45 price target.
The reiteration of an Overweight rating and the maintenance of a $45 price target by a reputable analyst could instill confidence in investors and positively influence Pfizer's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100